🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,57 USD

Máx. histórico

178,74

2144 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,17%

Rango 52 semanas

14,68 – 24,68

Variación hoy

-7,48%

Cierre anterior

18,99

Rango de hoy

17,44 – 18,92

Volumen hoy

1.859.162

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 16 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/01/2004 26,94 26,94 25,44 25,44 -3,64% 5,57% 70.467
27/01/2004 27,60 27,84 26,28 26,40 -2,65% 5,65% 78.767
26/01/2004 27,78 28,20 26,70 27,12 +1,35% 5,40% 138.850
23/01/2004 26,52 27,00 26,04 26,76 +2,76% 3,62% 50.617
22/01/2004 27,06 27,36 25,92 26,04 -4,19% 5,32% 63.067
21/01/2004 28,20 28,20 27,00 27,18 -4,63% 4,26% 52.500
20/01/2004 27,78 28,50 27,24 28,50 +4,17% 4,54% 84.867
16/01/2004 26,70 27,60 26,10 27,36 +2,93% 5,62% 40.933
15/01/2004 27,12 27,30 26,46 26,58 -3,49% 3,10% 57.867
14/01/2004 28,14 28,20 27,30 27,54 -1,29% 3,20% 42.350
13/01/2004 27,78 28,20 27,00 27,90 +0,43% 4,32% 52.000
12/01/2004 29,10 29,10 27,66 27,78 +0,43% 4,95% 98.900
09/01/2004 29,70 29,76 27,30 27,66 +4,77% 8,28% 262.867
08/01/2004 25,20 26,70 25,20 26,40 +4,27% 5,95% 122.217
07/01/2004 24,66 25,32 24,54 25,32 +1,93% 3,16% 47.233
06/01/2004 24,90 25,08 24,30 24,84 -0,24% 3,13% 59.250
05/01/2004 24,78 25,20 24,36 24,90 +1,72% 3,39% 63.900
02/01/2004 24,66 25,14 24,18 24,48 +0,25% 3,89% 41.467
31/12/2003 25,02 25,50 24,36 24,42 -3,33% 4,56% 83.400
30/12/2003 26,04 26,34 25,20 25,26 -2,09% 4,38% 51.467
29/12/2003 25,62 25,98 25,50 25,80 +0,47% 1,87% 35.267
26/12/2003 25,80 25,92 25,32 25,68 -0,47% 2,33% 9.400
24/12/2003 25,50 26,10 24,96 25,80 +1,18% 4,47% 24.217
23/12/2003 25,98 26,16 24,96 25,50 +2,16% 4,62% 62.200
22/12/2003 24,48 25,14 24,12 24,96 +0,48% 4,17% 29.500
19/12/2003 25,44 25,50 24,12 24,84 -1,43% 5,42% 34.150
18/12/2003 26,10 26,10 24,30 25,20 -0,71% 6,90% 40.450
17/12/2003 24,84 26,10 24,54 25,38 +3,17% 6,28% 54.117
16/12/2003 24,06 24,84 23,88 24,60 +1,99% 3,99% 38.317
15/12/2003 25,50 25,68 24,12 24,12 -4,74% 6,12% 37.867